NICE TAs

15/11/2023

ID4031: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer

30/10/2025

ID6378: Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721)

31/10/2025

TA1102: Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)

31/10/2025

ID5082: Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments

14/11/2025

ID6415: Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency

14/11/2025

ID6470: Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy

03/12/2025

ID6294: Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645)

25/02/2026

TA1136: bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer

11/03/2026

TA1139: Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment

02/03/2026

TA1138: Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer

25/02/2026

TA1137: canagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)

19/02/2026

TA1135: Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal)

18/02/2026

TA1134: Dupilumab for treating severe chronic rhinosinusitis with nasal polyps

18/02/2026

TA1133: Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma

18/02/2026

HST34: Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (terminated appraisal)

18/02/2026

HST34: Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2

17/02/2026

TA1132: Ruxolitinib for treating moderate to severe chronic graft versus host disease after an allogeneic stem cell transplant in people 28 days to 17 years (terminated appraisal)

12/02/2026

TA1129: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

12/02/2026

TA1131: Obinutuzumab with mycophenolate mofetil for treating lupus nephritis

11/02/2026

TA1130: Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer